Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
作者信息
Elnaggar Muhammad, Agte Sarita, Restrepo Paula, Ram Meghana, Melnekoff David, Adamopoulos Christos, Stevens Mark M, Kappes Katerina, Leshchenko Violetta, Verina Daniel, Jagannath Sundar, Poulikakos Poulikos I, Parekh Samir, Laganà Alessandro
机构信息
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x.
Abstract
摘要
相似文献
1
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.更正：三联丝裂原活化蛋白激酶（MAPK）抑制挽救了一名复发的、患有BRAF V600E亚克隆突变的抗B细胞成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞疗法多发性骨髓瘤患者。
J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x.
2
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.三重 MAPK 抑制挽救了一例复发的 BCMA CAR-T 细胞治疗后多发性骨髓瘤患者，该患者存在 BRAF V600E 亚克隆突变。
J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3.
3
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
4
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.抗 BCMA CAR-T 细胞疗法在伴有髓外疾病的复发/难治性多发性骨髓瘤患者中的应用：两项临床试验的单中心分析。
Front Immunol. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866. eCollection 2021.
5
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].[两例在鼠源BCMA CAR-T细胞治疗后进展的难治性多发性骨髓瘤患者的人源化BCMA CAR-T细胞挽救治疗]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):502-507. doi: 10.3760/cma.j.issn.0253-2727.2021.06.010.
6
Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.复发/难治性多发性骨髓瘤患者接受 BCMA CAR-T 细胞治疗后发生肿瘤溶解综合征的风险因素。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Apr 25;51(2):144-150. doi: 10.3724/zdxbyxb-2022-0038.
7
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
8
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.来那度胺增强抗 BCMA CAR-T 治疗复发/难治性多发性骨髓瘤的疗效：一例病例报告及文献复习。
Cancer Immunol Immunother. 2022 Jan;71(1):39-44. doi: 10.1007/s00262-021-02959-8. Epub 2021 May 18.
9
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.抗 BCMA CAR-T 细胞治疗浆细胞异常：POEMS 综合征和多发性骨髓瘤病例报告。
J Hematol Oncol. 2018 Oct 22;11(1):128. doi: 10.1186/s13045-018-0672-7.
10
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.一项1期多中心研究，评估自体抗BCMA嵌合抗原受体T细胞疗法KITE-585在复发/难治性多发性骨髓瘤患者中的安全性和有效性。
Am J Cancer Res. 2021 Jun 15;11(6):3285-3293. eCollection 2021.
本文引用的文献
1
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.三重 MAPK 抑制挽救了一例复发的 BCMA CAR-T 细胞治疗后多发性骨髓瘤患者，该患者存在 BRAF V600E 亚克隆突变。
J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3.
Zotero 插件